Arcturus Therapeutics Begins Operations in Janssen Labs

March 4, 2013

FOR IMMEDIATE RELEASE

RNAi Delivery Technology Specialists to Develop and Advance Novel Therapeutics for Rare Diseases

SAN DIEGO, Calif., March 4, 2013 – Arcturus Therapeutics, Inc., a company on the forefront of research and development of RNAi technologies, today announced it is located in Janssen Labs at Janssen Research & Development, LLC in San Diego, CA. The 30,000-square-foot Janssen Labs is a state-of-the-art laboratory focused on life science innovation and houses start-up companies pursuing new technologies and platforms to advance medical care.

Arcturus Therapeutics was founded in 2013 to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment. At Janssen Labs, Arcturus will have rapid access to flexible, turnkey modular wet lab units, as well as core research equipment and administrative business systems – and aims to accelerate research efforts at this highly revered incubator.

“We’re proud to be one of the few entrepreneurial companies selected to take part in Janssen Labs,” said Joseph E. Payne, president and CEO, Arcturus. “We are working diligently to discover solutions to address the world’s more difficult healthcare challenges, and we anticipate our discoveries will positively impact the RNAi community, as well as the world at large.”

“We’re pleased to have our operations located in this prestigious lab community,” said Pad Chivukula, COO & CSO, Arcturus. “Janssen Labs will provide Arcturus with access to exceptional facilities and opportunities to collaborate with leading scientists and other innovative life science companies with a comprehensive portfolio of cutting-edge technologies.”

About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Calif., Arcturus Therapeutics is poised to become an industry leader in the application of RNAi technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of therapeutic modalities, Arcturus is on the forefront of research and development of nanoparticle siRNA drug delivery systems. For more information, visit us at www.ArcturusRx.com.

# # #